286 related articles for article (PubMed ID: 34637965)
1. Chronic Graft-versus-Host Disease, Nonrelapse Mortality, and Disease Relapse in Older versus Younger Adults Undergoing Matched Allogeneic Peripheral Blood Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Analysis.
Bhatt VR; Wang T; Chen K; Kitko CL; MacMillan ML; Pidala JA; Al Malki MM; Badawy SM; Beitinjaneh A; Ganguly S; Hamilton B; Hildebrandt GC; Lekakis LJ; Liu H; Maziarz RT; Modi D; Murthy HS; Preussler JM; Sharma A; Spellman SR; Arora M; Lee SJ
Transplant Cell Ther; 2022 Jan; 28(1):34-42. PubMed ID: 34637965
[TBL] [Abstract][Full Text] [Related]
2. Younger Matched Unrelated Donors Confer Decreased Relapse Risk Compared to Older Sibling Donors in Older Patients with B Cell Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.
Abid MB; Estrada-Merly N; Zhang MJ; Chen K; Bredeson C; Allan D; Sabloff M; Marks DI; Litzow M; Hourigan C; Kebriaei P; Saber W
Transplant Cell Ther; 2023 Oct; 29(10):611-618. PubMed ID: 37481243
[TBL] [Abstract][Full Text] [Related]
3. Impact of Donor Age on Allogeneic Hematopoietic Cell Transplantation Outcomes in Older Adults with Acute Myeloid Leukemia.
Abid MB; Estrada-Merly N; Zhang MJ; Chen K; Allan D; Bredeson C; Sabloff M; Guru Murthy GS; Badar T; Hashmi S; Aljurf M; Litzow MR; Kebriaei P; Hourigan CS; Saber W
Transplant Cell Ther; 2023 Sep; 29(9):578.e1-578.e9. PubMed ID: 37406882
[TBL] [Abstract][Full Text] [Related]
4. Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation.
Saad A; Lamb L; Wang T; Hemmer MT; Spellman S; Couriel D; Alousi A; Pidala J; Abdel-Azim H; Agrawal V; Aljurf M; Beitinjaneh AM; Bhatt VR; Buchbinder D; Byrne M; Cahn JY; Cairo M; Castillo P; Chhabra S; Diaz MA; Farhan S; Floisand Y; Frangoul HA; Gadalla SM; Gajewski J; Gale RP; Gandhi M; Gergis U; Hamilton BK; Hematti P; Hildebrandt GC; Kamble RT; Kanate AS; Khandelwal P; Lazaryan A; MacMillan M; Marks DI; Martino R; Mehta PA; Nishihori T; Olsson RF; Patel SS; Qayed M; Rangarajan HG; Reshef R; Ringden O; Savani BN; Schouten HC; Schultz KR; Seo S; Shaffer BC; Solh M; Teshima T; Urbano-Ispizua A; Verdonck LF; Vij R; Waller EK; William B; Wirk B; Yared JA; Yu LC; Arora M; Hashmi S
Biol Blood Marrow Transplant; 2019 Sep; 25(9):1875-1883. PubMed ID: 31085303
[TBL] [Abstract][Full Text] [Related]
5. Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning.
Weisdorf D; Zhang MJ; Arora M; Horowitz MM; Rizzo JD; Eapen M
Biol Blood Marrow Transplant; 2012 Nov; 18(11):1727-33. PubMed ID: 22766220
[TBL] [Abstract][Full Text] [Related]
6. Higher Total Body Irradiation Dose Intensity in Fludarabine/TBI-Based Reduced-Intensity Conditioning Regimen Is Associated with Inferior Survival in Non-Hodgkin Lymphoma Patients Undergoing Allogeneic Transplantation.
Hamadani M; Khanal M; Ahn KW; Litovich C; Chow VA; Eghtedar A; Karmali R; Winter A; Fenske TS; Sauter C; Kharfan-Dabaja MA; Awan FT
Biol Blood Marrow Transplant; 2020 Jun; 26(6):1099-1105. PubMed ID: 32165327
[TBL] [Abstract][Full Text] [Related]
7. Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation.
Chhabra S; Visotcky A; Pasquini MC; Zhu F; Tang X; Zhang MJ; Thompson R; Abedin S; D'Souza A; Dhakal B; Drobyski WR; Fenske TS; Jerkins JH; Douglas Rizzo J; Runaas L; Saber W; Shah NN; Shaw BE; Horowitz MM; Hari PN; Hamadani M
Biol Blood Marrow Transplant; 2020 Oct; 26(10):1876-1885. PubMed ID: 32653622
[TBL] [Abstract][Full Text] [Related]
8. Donor Age and Non-Relapse Mortality: Study of Their Association after HLA-Matched Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome.
Kadri Y; Phan M; Bambace N; Bernard L; Cohen S; Delisle JS; Kiss T; Lachance S; Roy DC; Sauvageau G; Veilleux O; Roy J; Ahmad I
Curr Oncol; 2022 Aug; 29(8):5955-5962. PubMed ID: 36005208
[TBL] [Abstract][Full Text] [Related]
9. Outcome of Haploidentical Peripheral Blood Allografts Using Post-Transplantation Cyclophosphamide Compared to Matched Sibling and Unrelated Donor Bone Marrow Allografts in Pediatric Patients with Hematologic Malignancies: A Single-Center Analysis.
Srinivasan A; Raffa E; Wall DA; Schechter T; Ali M; Chopra Y; Kung R; Chiang KY; Krueger J
Transplant Cell Ther; 2022 Mar; 28(3):158.e1-158.e9. PubMed ID: 34838785
[TBL] [Abstract][Full Text] [Related]
10. European Group for Blood and Marrow Transplantation score correlates with outcomes of older patients undergoing allogeneic hematopoietic stem cell transplantation.
Chien SH; Liu YC; Liu CJ; Ko PS; Wang HY; Hsiao LT; Lin JS; Chiou TJ; Liu CY; Gau JP
J Chin Med Assoc; 2020 Mar; 83(3):238-244. PubMed ID: 31904659
[TBL] [Abstract][Full Text] [Related]
11. Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research.
Arai S; Arora M; Wang T; Spellman SR; He W; Couriel DR; Urbano-Ispizua A; Cutler CS; Bacigalupo AA; Battiwalla M; Flowers ME; Juckett MB; Lee SJ; Loren AW; Klumpp TR; Prockup SE; Ringdén OT; Savani BN; Socié G; Schultz KR; Spitzer T; Teshima T; Bredeson CN; Jacobsohn DA; Hayashi RJ; Drobyski WR; Frangoul HA; Akpek G; Ho VT; Lewis VA; Gale RP; Koreth J; Chao NJ; Aljurf MD; Cooper BW; Laughlin MJ; Hsu JW; Hematti P; Verdonck LF; Solh MM; Norkin M; Reddy V; Martino R; Gadalla S; Goldberg JD; McCarthy PL; Pérez-Simón JA; Khera N; Lewis ID; Atsuta Y; Olsson RF; Saber W; Waller EK; Blaise D; Pidala JA; Martin PJ; Satwani P; Bornhäuser M; Inamoto Y; Weisdorf DJ; Horowitz MM; Pavletic SZ;
Biol Blood Marrow Transplant; 2015 Feb; 21(2):266-74. PubMed ID: 25445023
[TBL] [Abstract][Full Text] [Related]
12. [Impact of chronic graft-versus-host disease on long-term outcome after allogeneic hematopoietic cell transplantation in adult acute lymphoblastic leukemia].
Wojnar J; Giebel S; Hołowiecka-Goral A; Krawczyk-Kuliś M; Markiewicz M; Stella-Hołowiecka B; Wylezoł I
Pol Arch Med Wewn; 2006 Jul; 116(1):671-7. PubMed ID: 17340974
[TBL] [Abstract][Full Text] [Related]
13. A Comparison of the Myeloablative Conditioning Regimen Fludarabine/Busulfan with Cyclophosphamide/Total Body Irradiation, for Allogeneic Stem Cell Transplantation in the Modern Era: A Cohort Analysis.
Gooptu M; Kim HT; Ho VT; Alyea EP; Koreth J; Armand P; Ritz J; Nikiforow S; Glotzbecker BE; Nageshwar P; Soiffer RJ; Antin JH; Cutler CS
Biol Blood Marrow Transplant; 2018 Aug; 24(8):1733-1740. PubMed ID: 29555313
[TBL] [Abstract][Full Text] [Related]
14. Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome.
McClune BL; Weisdorf DJ; Pedersen TL; Tunes da Silva G; Tallman MS; Sierra J; Dipersio J; Keating A; Gale RP; George B; Gupta V; Hahn T; Isola L; Jagasia M; Lazarus H; Marks D; Maziarz R; Waller EK; Bredeson C; Giralt S
J Clin Oncol; 2010 Apr; 28(11):1878-87. PubMed ID: 20212255
[TBL] [Abstract][Full Text] [Related]
15. CD34
Barba P; Martino R; Zhou Q; Cho C; Castro-Malaspina H; Devlin S; Esquirol A; Giralt S; Jakubowski AA; Caballero D; Maloy M; Papadopoulos EB; Piñana JL; Fox ML; Márquez-Malaver FJ; Valcárcel D; Solano C; López-Corral L; Sierra J; Perales MA
Biol Blood Marrow Transplant; 2018 May; 24(5):964-972. PubMed ID: 29305194
[TBL] [Abstract][Full Text] [Related]
16. Presalvage International Staging System Stage and Other Important Outcome Associations in CD34
Bryant AR; Hilden P; Giralt S; Chung DJ; Maloy M; Landau H; Landgren O; Scordo M; Shah G; Smith EL; O'Reilly RJ; Perales MA; Koehne G
Biol Blood Marrow Transplant; 2020 Jan; 26(1):58-65. PubMed ID: 31493537
[TBL] [Abstract][Full Text] [Related]
17. Ocular Chronic Graft-versus-Host Disease and Its Relation to Other Organ Manifestations and Outcomes after Allogeneic Hematopoietic Cell Transplantation.
Jeppesen H; Gjærde LK; Lindegaard J; Julian HO; Heegaard S; Sengeløv H
Transplant Cell Ther; 2022 Dec; 28(12):833.e1-833.e7. PubMed ID: 36002105
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Patient Age Groups in Transplantation for Myelodysplastic Syndrome: The Medicare Coverage With Evidence Development Study.
Atallah E; Logan B; Chen M; Cutler C; Deeg J; Jacoby M; Champlin R; Nishihori T; Confer D; Gajewski J; Farnia S; Greenberg P; Warlick E; Weisdorf D; Saber W; Horowitz MM; Rizzo JD
JAMA Oncol; 2020 Apr; 6(4):486-493. PubMed ID: 31830234
[TBL] [Abstract][Full Text] [Related]
19. Donor-Recipient Matching for KIR Genotypes Reduces Chronic GVHD and Missing Inhibitory KIR Ligands Protect against Relapse after Myeloablative, HLA Matched Hematopoietic Cell Transplantation.
Faridi RM; Kemp TJ; Dharmani-Khan P; Lewis V; Tripathi G; Rajalingam R; Daly A; Berka N; Storek J; Masood Khan F
PLoS One; 2016; 11(6):e0158242. PubMed ID: 27341514
[TBL] [Abstract][Full Text] [Related]
20. Incidence, Risk Factors, and Outcomes of Chronic Graft-versus-Host Disease in Pediatric Patients with Hematologic Malignancies after T Cell-Replete Myeloablative Haploidentical Hematopoietic Stem Cell Transplantation with Antithymocyte Globulin/Granulocyte Colony-Stimulating Factor.
Tang FF; Cheng YF; Xu LP; Zhang XH; Yan CH; Han W; Chen YH; Huang XJ; Wang Y
Biol Blood Marrow Transplant; 2020 Sep; 26(9):1655-1662. PubMed ID: 32504861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
